Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 12/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.30 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.30 |
| ▸ | METAP1 | P53582 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1023835 | 0.74 | ADORA2A (0.48) | ADORA2AADORA1ADORA3ADORA2BALDH1A1 | |
| SCHEMBL536868 | 0.66 | — | — | |
| SCHEMBL536980 | 0.66 | DPP4 (0.34) | — | |
| SCHEMBL8884479 | 0.66 | — | — | |
| SCHEMBL28211480 | 0.66 | ADORA2A (0.59) | ADORA2AADORA1HSP90AA1ADORA3ADORA2B | |
| SCHEMBL3684455 | 0.65 | ADORA2A (1.00) | ADORA2AADORA1HSP90AA1ADORA3ADORA2B | |
| SCHEMBL887879 | 0.65 | ADORA2A (0.50) | ADORA2AADORA1HSP90AA1ADORA3ADORA2B | |
| SCHEMBL887880 | 0.65 | PDPK1 (0.51) | ADORA2AADORA1HSP90AA1PDPK1 | |
| SCHEMBL1025895 | 0.63 | CCNA2 (0.35) | — | |
| SCHEMBL3503498 | 0.63 | ADORA2A (0.63) | ADORA2AADORA1HSP90AA1TGFBR1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960543-B2 | Nucleoside or nucleotide derivative and use thereof | RIKEN (JP) | 2011-06-14 | — | — | US | claimed |
| US-20110087015-A1 | Nucleoside and nucleotide having an unnatural base and use thereof | RIKEN (JP) | 2011-04-14 | — | — | US | claimed |
| US-20090275017-A1 | Novel Nucleoside or Nucleotide Derivative and Use Thereof | RIKEN (JP) | 2009-11-05 | — | — | US | claimed |
| EP-1816130-A1 | NOVEL NUCLEOSIDE OR NUCLEOTIDE DERIVATIVE AND USE THEREOF | Riken (JP) | 2007-08-08 | — | — | EP | claimed |
| EP-4382603-A1 | ARTIFICIAL NUCLEIC ACID FOR INDUCING SPECIFIC THREE-DIMENSIONAL STRUCTURE | Sophia School Corporation (JP) | 2024-06-12 | — | — | EP | disclosed |
| US-20240093282-A1 | TARGET NUCLEIC ACID DETECTION DEVICE AND MANUFACTURING METHOD FOR SAME | RICOH COMPANY, LTD. (JP) | 2024-03-21 | — | — | US | disclosed |
| US-20230257423-A1 | COMPOSITIONS FOR TREATING EPITHELIAL BARRIER FUNCTION DISORDERS | INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (FR) | 2023-08-17 | — | — | US | disclosed |
| US-20230242915-A1 | SMALL INTERFERING DEOXYRIBONUCLEIC ACID (SIDNA) AGAINST METALLO-BETA LACTAMASE GENE | Cheshmenooshi, Bahareh (IR) | 2023-08-03 | — | — | US | disclosed |
| WO-2023112912-A1 | CONJUGATE COMPOUND AND METHOD FOR PRODUCING CONJUGATE COMPOUND | 株式会社日本触媒 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023013613-A1 | ARTIFICIAL NUCLEIC ACID FOR INDUCING SPECIFIC THREE-DIMENSIONAL STRUCTURE | 学校法人上智学院 | 2023-02-09 | — | — | WO | disclosed |
| WO-2022269463-A1 | TRUNCATED HYALURONAN SYNTHASE AND POLYNUCLEOTIDE ENCODING THE SAME | KERAMATI MALIHE (IR) | 2022-12-29 | — | — | WO | disclosed |
| US-20220411765-A1 | TRUNCATED HYALURONAN SYNTHASE AND POLYNUCLEOTIDE ENCODING THE SAME | Keramati, Malihe (IR) | 2022-12-29 | — | — | US | disclosed |
| EP-1921141-B1 | NOVEL ARTIFICIAL BASE PAIR AND USE THEREOF | RIKEN (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20100285598-A1 | Novel Artificial Base Pairs and Uses Thereof | RIKEN (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20100036111-A1 | METHOD FOR REPLICATING NUCLEIC ACIDS AND NOVEL UNNATURAL BASE PAIRS | RIKEN (JP) | 2010-02-11 | — | — | US | disclosed |
| US-20090275017-A1 | Novel Nucleoside or Nucleotide Derivative and Use Thereof | RIKEN (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1970445-A1 | METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS | Riken (JP) | 2008-09-17 | — | — | EP | disclosed |
| EP-1921141-A1 | NOVEL ARTIFICIAL BASE PAIR AND USE THEREOF | Riken (JP) | 2008-05-14 | — | — | EP | disclosed |
| EP-1816130-A1 | NOVEL NUCLEOSIDE OR NUCLEOTIDE DERIVATIVE AND USE THEREOF | Riken (JP) | 2007-08-08 | — | — | EP | disclosed |
| WO-2005026187-A1 | NUCLEOSIDE OR NUCLEOTIDE HAVING NONNATURAL BASE AND USE THEREOF | RIKEN (JP) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275017-A1 | Novel Nucleoside or Nucleotide Derivative and Use Thereof | DUT, NT5C3B, NT5C | ADORA2A 889/4885ADORA1 1454/4885HSP90AA1 4193/4885 |
| US-20100036111-A1 | METHOD FOR REPLICATING NUCLEIC ACIDS AND NOVEL UNNATURAL BASE PAIRS | POLM, POLL, POLRMT | ADORA2A 978/4885ADORA1 1354/4885HSP90AA1 2668/4885 |
| US-20100285598-A1 | Novel Artificial Base Pairs and Uses Thereof | POLRMT, RNGTT, POLN | ADORA2A 1513/4885ADORA1 995/4885HSP90AA1 2196/4885 |
| US-20230257423-A1 | COMPOSITIONS FOR TREATING EPITHELIAL BARRIER FUNCTION DISORDERS | FABP2, SLC10A2, VIP | ADORA2A 3503/4885ADORA1 2659/4885HSP90AA1 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.